Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)

Targeting the PD-1/PD-L1 immunologic checkpoint with monoclonal antibodies has provided unprecedented results in cancer treatment in the recent years. Development of chemical inhibitors for this pathway lags the antibody development because of insufficient structural information. The first nonpeptid...

Descripción completa

Detalles Bibliográficos
Autores principales: Zak, Krzysztof M., Grudnik, Przemyslaw, Guzik, Katarzyna, Zieba, Bartosz J., Musielak, Bogdan, Dömling, Alexander, Dubin, Grzegorz, Holak, Tad A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058683/
https://www.ncbi.nlm.nih.gov/pubmed/27083005
http://dx.doi.org/10.18632/oncotarget.8730

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058683/
https://www.ncbi.nlm.nih.gov/pubmed/27083005
http://dx.doi.org/10.18632/oncotarget.8730

Ejemplares similares